Stable, antiinflammatory isothiocyanates from moringa may prevent and treat IBD

辣木中稳定的抗炎异硫氰酸盐可以预防和治疗 IBD

基本信息

批准号：
9123529
负责人：
Youjin Kim
金额：
$ 7.11万
依托单位：
NUTRASORB, LLC
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-01 至 2017-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9123529
关键词：
Acute Affect Africa Anti-Inflammatory Agents Anti-inflammatory Apoptosis Area Asia Biological Availability Blood Botanicals Brassicaceae Broccoli - dietary Caco-2 Cells California Cell Cycle Arrest Cell model Chemicals Chemoprotective Agent Chronic Chronic Disease Cleaved cell Climate Clinical Collaborations Data Diet Digestion Disease Edible Plants Enterocytes Enzymes Epithelial Excision Family Feces Food Geographic Locations Glucosinolates Goals Hawaii Health High Fat Diet Human In Vitro Individual Inflammation Inflammatory Inflammatory Bowel Diseases Intervention Intestines Isothiocyanates Laboratories Link MAP Kinase Gene Malignant Neoplasms Mechanics Medicine Metabolic Biotransformation Methods Moringa Moringa oleifera Mus Myrosinase Natural Products Nutrient Nutritional Oral PTGS2 gene Pathway interactions Personal Satisfaction Pharmacodynamics Phase Plant Leaves Plants Powder dose form Preparation Prevention Procedures Process Property Publishing Rattus Reaction Reporting Research Risk Side Skeletal Myoblasts Skeleton Small Business Innovation Research Grant Small Intestines Sodium Dextran Sulfate Sulforaphane TNF gene Taste Perception Technology Thiocyanates Tissues Toxic effect Toxicology Traditional Medicine Ulcerative Colitis Universities Vitamins Weight Wistar Rats Work Zambia acute toxicity analog aqueous commercialization cost efficient cruciferous vegetable cytotoxicity design experience feeding in vitro Model in vivo Model inflammatory marker innovation large scale production mouse model novel novel strategies prevent product development sugar validation studies

项目摘要

DESCRIPTION (provided by applicant): This Phase I SBIR project aims to preclinically characterize an innovative and proprietary botanical product targeting chronic inflammatory conditions such as inflammatory bowel disease (IBD). Our objective is to provide experimental support for the hypothesis that anti-inflammatory isothiocyanates (ITCs) naturally produced in the edible leaves of Moringa oleifera Lam. (moringa) after mechanical wounding provide stable, highly efficacious and practical alternatives to instable and volatile ITCs produced by plants of the crucifer family (Brassicaceae), such as broccoli. Moringa leaves are historically used as a nutritious food and traditional medicine throughout South Asia and Africa. They contain high levels of nutrients, vitamins, and beneficial phytoactives. These phytoactives include unique, sugar-modified aromatic glucosinolates that can be converted to bioactive and stable moringa isothiocyanates (MICs) in wounded leaves. We have developed a novel, simple and proprietary aqueous extraction/biotransformation method, which effectively converts moringa glucosinolates into MICs resulting in good-tasting, shelf-stable, food-grade, moringa concentrate (MC) containing at least 3% of MICs. Preliminary studies have shown that MICs equal or exceed the bioactivity of sulforaphane, a well-known ITC from broccoli. Both MC and MICs strongly reduced the expression and levels of inflammatory markers, such as iNOS, IL- 1ß, and TNF in in vitro models as well TNF levels in intestinal tissue and feces of mice fed a high fat diet. The proposed work, carried out in close collaboration with the laboratory of Dr. Ilya Raskin of Rutgers University (a leading expert in botanicals and inflammation) and three consultants, experienced in various aspects of natural products and IBD, will assess bioavailability and toxicology of MICs delivered in MC. We will further investigate anti-inflammatory effects of MC and MICs in an in vitro Caco-2 cell model with the goal of elucidating the mechanism of action of MICs and study the effects of MC in the dextran sodium-sulfate (DSS)-induced mouse model of acute and chronic ulcerative colitis. Finally, we will investigate and compare MIC content of various moringa cultivars growing in diverse climatic and geographic regions and define and optimize commercial scale MC manufacturing methods, such as wounding, residue removal and drying.

描述（由适用提供）：该I期SBIR项目旨在临床上描述靶向慢性炎症状况（例如炎症性肠病（IBD））的创新和专有植物产品。我们的目标是为莫林加·奥利法拉·洛姆（Moringa oleifera Lam）的可食用叶片自然产生的抗炎异氰酸酯（ITC）提供实验支持。（Moringa）在机械上损伤后，可提供稳定，高效且实用的替代方案，用于由十字花科植物（Brassicaceae）（例如西兰花）产生的稳定和挥发性ITC。在整个南亚和非洲，辣木叶历史上被用作营养食品和传统医学。它们含有高水平的养分，维生素和有益的植物活性。这些植物活性包括可转化为受伤叶片中的生物活性和稳定的异硫氰酸盐（MIC）的独特糖改性芳香糖醇。我们已经开发了一种新型，简单且专有的水性提取/生物转化方法，该方法有效地将辣木葡萄糖素转化为MIC，从而产生了至少3％的MIC的良好，保存稳定，食品级，食品级，辣木浓缩（MC）。初步研究表明，麦克风相等或超过了西兰花的众所周知的ITC硫烷的生物活性。 MC和MIC都大大降低了炎症标记的表达和水平，例如Inos，IL-1ß和TNF体外模型，以及肠道组织中TNF水平以及喂养高脂饮食的小鼠的粪便。拟议的工作与罗格斯大学（Rutgers University）的Ilya Raskin博士（植物和炎症领域的领先专家）密切合作，在天然产品和IBD的各个方面经验丰富的三位顾问将评估MC在MC中提供的MICS的生物利用度和毒理学。我们将进一步研究MC和MIC在体外CACO-2细胞模型中的抗炎作用，目的是阐明MIC的作用机理，并研究MC在葡聚糖钠硫酸盐（DSS）诱导的急性和慢性溃疡性溃疡性溃疡性结肠炎的小鼠模型中的影响。最后，我们将研究和比较在潜水员气候和地理区域种植的各种辣木品种的MIC含量，并定义和优化商业规模的MC制造方法，例如伤害，退休清除和干燥。